首页
400-620-6333
IL-33
有货
切换导航
搜索
基本描述
| 产品名称 | IL-33 |
|---|
产品规格参数
| CAS编号和信息 | rp174305 |
|---|
数据库链接
| UniProtKB | O95760 |
|---|---|
| Wikipedia | Il-33 |
| Ensembl Gene | ENSG00000137033 |
靶标
| Target ID | 1906 |
|---|---|
| 名称 | Interleukin-33 receptor |
| 缩写名 | SHP2 |
| 家族 | Immunoglobulin-like family of IL-1 receptors |
| 别名 | GPR167 |
关联配体
| Ligand ID | 5880 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 名称 | IL-33 | ||||||||||
| 别名 | IL-1F11 | ||||||||||
| 类别 | Peptide | ||||||||||
| 学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide | ||||||||||
| 生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
||||||||||
| 评价 |
IL-33 is a pleiotropic IL-1 family cytokine that can both promote type 2 inflammation and also drive immunoregulation through expansion of Foxp3+Treg cells. The outcomes of IL-33 activity appear to depend on the cells that produce it, either myeloid dendritic cells (DC) or epithelial cells The ST2/IL-33 axis is recognised as playing an important role in the development/exacerbation of IgE-dependent inflammations such as asthma and atopic dermatitis |
||||||||||
| 配体家族 | Interleukins | ||||||||||
| 基因/前体 |
|
||||||||||
| 单字母多肽序列 | SITGISPITEYLASLSTYNDQSITFALEDESYEIYVEDLKKDEKKDKVLLSYYESQHPSNESGDGVDGKMLMVTLSPTKDFWLHANNKEHSVELHKCEKPLPDQAFFVLHNMHSNCVSFECKTDPGVFIGVKDNHLALIKVDSSENLCTENILFKLSET | ||||||||||
| 三字母多肽序列 | Ser-Ile-Thr-Gly-Ile-Ser-Pro-Ile-Thr-Glu-Tyr-Leu-Ala-Ser-Leu-Ser-Thr-Tyr-Asn-Asp-Gln-Ser-Ile-Thr-Phe-Ala-Leu-Glu-Asp-Glu-Ser-Tyr-Glu-Ile-Tyr-Val-Glu-Asp-Leu-Lys-Lys-Asp-Glu-Lys-Lys-Asp-Lys-Val-Leu-Leu-Ser-Tyr-Tyr-Glu-Ser-Gln-His-Pro-Ser-Asn-Glu-Ser-Gly-Asp-Gly-Val-Asp-Gly-Lys-Met-Leu-Met-Val-Thr-Leu-Ser-Pro-Thr-Lys-Asp-Phe-Trp-Leu-His-Ala-Asn-Asn-Lys-Glu-His-Ser-Val-Glu-Leu-His-Lys-Cys-Glu-Lys-Pro-Leu-Pro-Asp-Gln-Ala-Phe-Phe-Val-Leu-His-Asn-Met-His-Ser-Asn-Cys-Val-Ser-Phe-Glu-Cys-Lys-Thr-Asp-Pro-Gly-Val-Phe-Ile-Gly-Val-Lys-Asp-Asn-His-Leu-Ala-Leu-Ile-Lys-Val-Asp-Ser-Ser-Glu-Asn-Leu-Cys-Thr-Glu-Asn-Ile-Leu-Phe-Lys-Leu-Ser-Glu-Thr | ||||||||||
| 翻译后修饰 | |||||||||||
| 化学修饰 |
参考文献
| 1. Hsu CL, Neilsen CV, Bryce PJ. (2010) IL-33 is produced by mast cells and regulates IgE-dependent inflammation.. PLoS ONE, 5 (8): (e11944). [PMID:20689814] |
| 2. Lefran?ais E, Cayrol C. (2012) Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members.. Eur Cytokine Netw, 23 (4): (120-7). [PMID:23306193] |
| 3. Cayrol C, Girard JP. (2014) IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy.. Curr Opin Immunol, 31 (13): (31-7). [PMID:25278425] |
| 4. Bandara G, Beaven MA, Olivera A, Gilfillan AM, Metcalfe DD. (2015) Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.. Eur J Immunol, 45 (11): (3034-44). [PMID:26256265] |
| 5. Hung LY, Tanaka Y, Herbine K, Pastore C, Singh B, Ferguson A, Vora N, Douglas B, Zullo K, Behrens EM et al.. (2020) Cellular context of IL-33 expression dictates impact on anti-helminth immunity.. Sci Immunol, 5 (53): (1755-70). [PMID:33188058] |
| 6. Chen YL, Gutowska-Owsiak D, Hardman CS, Westmoreland M, MacKenzie T, Cifuentes L, Waithe D, Lloyd-Lavery A, Marquette A, Londei M et al.. (2019) Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis.. Sci Transl Med, 11 (515): (1755-70). [PMID:31645451] |
产品问答
产品问答
上海阿拉丁生化科技股份有限公司
? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任
危险品化学品经营许可证（带存储）